

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for April 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Zopiclone	Imovane	ZOPICLONE	3.75 mg	tablet	02549271
Dr. Reddy's Laboratories Canada Inc.	Reddy-Nilotinib	Tasigna	NILOTINIB	150 mg	capsule	02556634
Dr. Reddy's Laboratories Canada Inc.	Reddy-Nilotinib	Tasigna	NILOTINIB	200 mg	capsule	02556642

Sivem Pharmaceuticals	Desvenlafaxine	Pristiq	DESVENLAFAXINE	50 mg	tablet (extended-release)	02554968
Sivem Pharmaceuticals	Desvenlafaxine	Pristiq	DESVENLAFAXINE	100 mg	tablet (extended-release)	02554976
Mantra Pharma Inc.	M-Citalopram	Celexa	CITALOPRAM HYDROBROMIDE	10 mg	tablet	02532123
Apotex Inc.	Apo-Butalbital-Acetylsalicylic Acid-Caffeine	Fiorinal	BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE	50 mg / 330 mg / 40 mg	capsule	02554690